Genes encoding the various components of BAF are mutated in at least 20% of human cancers making it an attractive target for novel antitumor therapies such as inhibitors of the bromodomains that occur in other BAF components.81, 82 Most of the fusion ORFs identified here (Figure 3) encode an N‐terminally truncated form of BCL11B that retains the six zinc finger domains. This evidence concerns the gene BCL11B and cancer.